MAOB and Alzheimer disease: Park et al. (2019) proposed that the MAO-B/GABA interaction may account for why the irreversible MAO-B-selective inhibitor l-deprenyl (selegiline) has been found to improve cognitive deficits in AD after short-term, but not long-term, administration.